421 related articles for article (PubMed ID: 21448449)
1. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
2. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Pal SK; Twardowski P; Sartor O
Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
[TBL] [Abstract][Full Text] [Related]
3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
5. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Figg WD; Figg WD
Cancer Biol Ther; 2010 Dec; 10(12):1233-4. PubMed ID: 21107022
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
Zhong L; Pon V; Srinivas S; Nguyen N; Frear M; Kwon S; Gong C; Malmstrom R; Wilson L
PLoS One; 2013; 8(5):e64275. PubMed ID: 23717582
[TBL] [Abstract][Full Text] [Related]
9. Cabazitaxel: a novel microtubule inhibitor.
Villanueva C; Bazan F; Kim S; Demarchi M; Chaigneau L; Thiery-Vuillemin A; Nguyen T; Cals L; Dobi E; Pivot X
Drugs; 2011 Jul; 71(10):1251-8. PubMed ID: 21770474
[TBL] [Abstract][Full Text] [Related]
10. Cabazitaxel in metastatic castration-resistant prostate cancer.
Yap TA; Pezaro CJ; de Bono JS
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1129-36. PubMed ID: 23098113
[TBL] [Abstract][Full Text] [Related]
11. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
12. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S
Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
[TBL] [Abstract][Full Text] [Related]
13. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
14. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
Altavilla A; Iacovelli R; Procopio G; Alesini D; Risi E; Campennì GM; Palazzo A; Cortesi E
Cancer Biol Ther; 2012 Sep; 13(11):1001-8. PubMed ID: 22825325
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel, a new taxane with favorable properties.
Bouchet BP; Galmarini CM
Drugs Today (Barc); 2010 Oct; 46(10):735-42. PubMed ID: 21076710
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
Keating GM
Drugs Aging; 2013 May; 30(5):359-65. PubMed ID: 23532557
[TBL] [Abstract][Full Text] [Related]
17. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
[TBL] [Abstract][Full Text] [Related]
18. Cabazitaxel: a novel drug for hormone-refractory prostate cancer.
Malhotra M; Dhingra R; Sharma T; Deep A; Narasimhan B; Phogat P; Sharma PC
Mini Rev Med Chem; 2013 May; 13(6):915-20. PubMed ID: 22950608
[TBL] [Abstract][Full Text] [Related]
19. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234
[TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]